Rising adoption of single‑gene noninvasive prenatal tests (NIPTs) is reshaping the U.S. prenatal genetics landscape, streamlining clinical decision‑making across aneuploidy and carrier screening and improving how providers approach genetic testing.
Findings from Dx Trends: Prenatal Genetics—Proprietary Survey of 169 Ob-Gyns and MFMs point to near-universal use of chromosomal condition testing, underscoring strong momentum for single-gene NIPTs. Authored by William Blair healthcare analyst Andrew Brackmann, CFA, the report also highlights a key inflection point: the ability to remove the need for paternal carrier screening when assessing fetal risk of inherited conditions would be “game changing,” potentially accelerating adoption across the sector. These advancements are beginning to influence genetic testing strategies and intensify competition among industry leaders.
For more information on William Blair’s healthcare equity research, contact us or your William Blair representative.